Recent Finacing
Recent Raise
Siolta Therapeutics develops defined-consortia live biotherapeutic products via its Precision Symbiotics Platform, advancing STMC-103H in phase 2 to prevent newborn atopic diseases and other preclinical programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Siolta Therapeutics.
